bioAffinity Technologies, Inc.
BIAF
Positions held
Your positionsBIAF isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $6.58M | Enterprise value | $2.05M | Trailing P/E | — | Forward P/E | -9.40 |
| PEG | — | Price / book | 0.68 | Beta | -1.25 | Dividend yield | 0.00% |
| Revenue growth | 19.0% | Earnings growth | — | Gross margin | 34.6% | Operating margin | -2.2% |
| Profit margin | -2.6% | ROE | -18.6% | ROA | -125.1% | Debt / equity | 0.38 |
| Current ratio | 1.44 | Free cash flow | -$6.91M | Analyst recommendation | none | Mean target | — |
| 52w high | $80.70 | 52w low | $4.56 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.4M | $1.5M | $1.4M | $1.3M | — |
| Op margin | -220.8% | -267.6% | -207.4% | -158.6% | -198.2% | — |
| Net income | -$3.4M | -$3.6M | -$3.1M | -$5.1M | -$4.1M | — |
| Gross margin | 28.0% | 31.3% | 41.5% | 34.8% | 19.9% | — |
| Gross profit | $0.4M | $0.4M | $0.6M | $0.5M | $0.3M | — |
| Operating income | -$3.3M | -$3.6M | -$3.2M | -$2.3M | -$2.5M | — |
- Revenue +12% vs prior quarter ($1.5M vs $1.4M).
- Gross margin 28% (was 31.3% prior quarter).
- Operating margin expanded to -220.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.1M | $9.4M | $2.5M | $0.0M | — |
| Op margin | -174.0% | -95.6% | -314.8% | -83511.5% | — |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | — |
| Gross margin | 30.8% | 36.1% | 31.3% | 90.3% | — |
| Gross profit | $1.9M | $3.4M | $0.8M | $0.0M | — |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Update: BioAffinity Technologies Prices $4 Million Registered Direct Offering
2026-10-08 · BioAffinity Technologies Prices $4 Million Registered Direct Offering
2026-10-08 · bioAffinity Technologies Receives Japanese Patent Allowance for CyPath Lung AI Diagnostic Test
2026-10-06 · bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
2026-09-28 · bioAffinity Technologies Builds Momentum for Non-Invasive Lung Cancer Detection
2026-09-22 · bioAffinity Technologies to Showcase Lung Cancer Test Data at Veterans’ Research Conference
2026-09-17 · Top Midday Gainers
Price (daily)
Full chart · RSI · MACD · patterns